Delpharm invests in Tours | The CDMO Delpharm confirms its strategy by investing in its manufacturing site in Tours, France. The project, initiated in April 2021, has resulted in a new building with state-of-the-art equipment such as isolators. The €28 million investment unveiled today, will be dedicated to the implementation of a sterile line entirely dedicated to the manufacture of pre-filled syringes and will enable Delpharm to produce between 25 and 30 million syringes per year. To meet demand, the company will offer a wide range of formats and materials: pre-filled syringes in glass or plastic, subcutaneous or intra-nasal with volumes from 1 to 50 ml. Delpharm plans to start production in the first quarter of 2023.